Literature DB >> 17178763

Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.

B Vander Cruyssen, F De Keyser, E Kruithof, H Mielants, F Van den Bosch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17178763      PMCID： PMC1798420          DOI： 10.1136/ard.2006.055541

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

Review 1.  Assessment of patients with psoriatic arthritis: a review of currently available measures.

Authors:  Dafna D Gladman; Philip Helliwell; Philip J Mease; Peter Nash; Christopher Ritchlin; William Taylor
Journal:  Arthritis Rheum       Date:  2004-01

2.  Evaluation of a functional index and an articular index in ankylosing spondylitis.

Authors:  M Dougados; A Gueguen; J P Nakache; M Nguyen; C Mery; B Amor
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.

Authors:  D O Clegg; D J Reda; E Mejias; G W Cannon; M H Weisman; T Taylor; E Budiman-Mak; W D Blackburn; F B Vasey; M L Mahowald; J J Cush; H R Schumacher; S L Silverman; F P Alepa; M E Luggen; M R Cohen; R Makkena; C M Haakenson; R H Ward; B J Manaster; R J Anderson; J R Ward; W G Henderson
Journal:  Arthritis Rheum       Date:  1996-12

4.  Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

Authors:  Filip Van Den Bosch; Elli Kruithof; Dominique Baeten; Annemie Herssens; Filip de Keyser; Herman Mielants; Eric M Veys
Journal:  Arthritis Rheum       Date:  2002-03

5.  Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis.

Authors:  A C Verhoeven; M Boers; S van Der Linden
Journal:  Ann Rheum Dis       Date:  2000-12       Impact factor: 19.103

6.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

7.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; D Furst; C Goldsmith; L M Katz; R Lightfoot; H Paulus; V Strand
Journal:  Arthritis Rheum       Date:  1995-06
  7 in total
  8 in total

1.  Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.

Authors:  Francesco Carubbi; Luigi Zugaro; Paola Cipriani; Armando Conchiglia; Lorenzo Gregori; Cristino Danniballe; Maria Letizia Pistoia; Vasiliki Liakouli; Piero Ruscitti; Francesco Ciccia; Giovanni Triolo; Carlo Masciocchi; Roberto Giacomelli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

2.  Remission in psoriatic arthritis.

Authors:  Kurt de Vlam; Rik J U Lories
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

3.  Remission in psoriatic arthritis: is it possible and how can it be predicted?

Authors:  Tajvur P Saber; C T Ng; Guillaume Renard; Bernadette M Lynch; Eliza Pontifex; Ceara A E Walsh; Alexia Grier; Marian Molloy; Barry Bresnihan; Oliver Fitzgerald; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

Review 4.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

5.  Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.

Authors:  Kristian Thorlund; Eric Druyts; J Antonio Aviña-Zubieta; Edward J Mills
Journal:  Biologics       Date:  2012-12-03

6.  Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.

Authors:  Eliza K Pontifex; Danielle M Gerlag; Martina Gogarty; Marjolein Vinkenoog; Adrian Gibbs; Ilse Burgman; Ursula Fearon; Barry Bresnihan; Paul Peter Tak; Robin G Gibney; Douglas J Veale; Oliver FitzGerald
Journal:  Arthritis Res Ther       Date:  2011-01-27       Impact factor: 5.156

7.  What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials.

Authors:  Sibel Bakirci Ureyen; Catherine Ivory; Umut Kalyoncu; Jacob Karsh; Sibel Zehra Aydin
Journal:  Rheumatol Adv Pract       Date:  2018-01-08

8.  Long-term remission and biologic persistence rates: 12-year real-world data.

Authors:  Kieran Murray; Matthew Turk; Yousef Alammari; Francis Young; Phil Gallagher; Tajvur Saber; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2021-01-13       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.